Golgi Neurosciences announces Breye Therapeutics to start Phase 1b/2a clinical trials
Milan (Italy) – Golgi Neurosciences Srl is thrilled to share an update from its portfolio company Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology. Breye Therapeutics has initiated phase 1b/2a clinical trial, with the scope to assess safety, tolerability, pharmacokinetics (PK) and early sign of biological activity following oral administration of Danegaptide.
Breye Therapeutics’ oral drug, Danegaptide, aims to the treatment of patients affected by Diabetic Macular Edema (DME). Danegaptide has progressed to this crucial stage with robust non-clinical in vitro and in vivo efficacy results, and it has proven safe in over 500 clinical trial participants.
This milestone marks a significant step forward in the development of orally available drugs for the treatment of ophthalmological disorders.